Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS—Meet-URO 26 Real-World Study

Autor: Patrikidou, Anna, Saieva, Calogero, Lee-Ying, Richard, Nuzzo, Pier Vitale, Zarif, Talal El, McClure, Heather, Davidsohn, Matthew, Eid, Marc, Spinelli, Gian Paolo, Catalano, Fabio, Cremante, Malvina, Fotia, Giuseppe, Rossetti, Sabrina, Valenca, Loana, Vauchier, Charles, Ottanelli, Carlotta, Andrade, Livia, Gennusa, Vincenzo, Mestre, Ricardo Pereira, Fornarini, Giuseppe, Pignata, Sandro, Procopio, Giuseppe, Santini, Daniele, Ravi, Praful, Sweeney, Christopher, Heng, Daniel, De Giorgi, Ugo, Fizazi, Karim, Russo, Antonio, Francini, Edoardo
Zdroj: In Clinical Genitourinary Cancer December 2024 22(6)
Databáze: ScienceDirect
Externí odkaz: